Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone injection at repeat caesarean section to prevent keloid scar recurrence
ACTRN12618000984291Phase 4Not yet recruiting
- Sponsor
- Westmead Hospital
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of triamcinolone acetonide in keloid (2 arms), sponsored by Westmead Hospital. Primary endpoints: Keloid formation after intervention and Change in scar appearance and characteristics. Planned start May 2019; status: not yet recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
keloid
Beyond the preview
Go deeper on ACTRN12618000984291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000984291.